Fig. 7: In vivo immune stimulation effect of Pd2Sn@GOx-SP.
From: Intermetallics triggering pyroptosis and disulfidptosis in cancer cells promote anti-tumor immunity
a Pattern diagram for remodeling the immunosuppressive TME. b Representative flow cytometry data and c the quantitative data of matured DCs in spleens after receiving diverse treatments (G1, control; G2, laser; G3, Pd2Sn-SP; G4, Pd2Sn@GOx-SP; G5, Pd2Sn@GOx-SP + laser). d Representative flow cytometry data and e the quantitative data of CD8+ T cells in spleens after receiving diverse treatments. f Representative flow cytometry data and g the quantitative data of IFN-γ level in tumor tissues after diverse treatments. h The corresponding quantitative data of CD8+ T cells in tumor tissues after receiving different treatments. i The corresponding quantitative data of M1-type macrophages (CD86+ and CD206− cells) in tumor. j Schematic diagram of the schedule for tumor rechallenge study. k Body weight changes of CT26 recurrence tumor-bearing mice with diverse treatments. l Tumor volume and m relative tumor volume of recurrence tumor in CT26 tumor-bearing mice with diverse treatments. n The corresponding quantitative data of IFN-γ level in recurrence tumor tissues. o Representative flow cytometry data of TEM (CD62L− and CD44+ cells) in spleens after receiving diverse treatments. Data are expressed as mean ± S.D. (n = 3) independent samples in (c, e, g–i, n), (n = 5) mice for each group in (k, m). Statistical significance is assessed by a two-way ANOVA with Tukey’s multiple comparisons test. Source data are provided as a Source Data file.
